BENDAMUSTINE IS NOT ASSOCIATED WITH AN INCREASE IN INFECTIONS - SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

被引：0
|
作者：
Gafter-Gvili, A. [1 ]
Gurion, R. [1 ]
Raanani, P. [1 ]
Shpilberg, O. [1 ]
Vidal, L. [1 ]
机构：
[1] Rabin Med Ctr, Inst Hematol, Petah Tiqwa, Israel
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P439
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [1] Bendamustine Is Not Associated With An Increase In Infections - Systematic Review and Meta-Analysis Of Randomized Controlled Trials
    Gafter-Gvili, Anat
    Gurion, Ronit
    Raanani, Pia
    Shpilberg, Ofer
    Vidal, Liat
    BLOOD, 2013, 122 (21)
  • [2] Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials
    Gafter-Gvili, Anat
    Gurion, Ronit
    Raanani, Pia
    Shpilberg, Ofer
    Vidal, Liat
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 424 - 431
  • [3] BENDAMUSTINE FOR PATIENTS WITH INDOLENT LYMPHOMA - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCT)
    Vidal, L.
    Gafter-Gvili, A.
    Gurion, R.
    Dreyling, M.
    Raanani, P.
    Shpilberg, O.
    ANNALS OF ONCOLOGY, 2011, 22 : 185 - 185
  • [4] Hypomethylating Agents-associated Infections-Systematic Review and Meta-analysis of Randomized Controlled Trials
    Shargian-Alon, Liat
    Gurion, Ronit
    Raanani, Pia
    Yahav, Dafna
    Gafter-Gvili, Anat
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (09): : 603 - +
  • [5] Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
    Zhu, Gui-Qi
    Zou, Zhuo-Lin
    Zheng, Ji-Na
    Chen, Da-Zhi
    Zou, Tian-Tian
    Shi, Ke-Qing
    Zheng, Ming-Hua
    MEDICINE, 2016, 95 (09)
  • [6] Systematic Review, Meta-Analysis and Randomized Controlled Trials in Cytopathology
    AbdullGaffar, Badr
    ACTA CYTOLOGICA, 2012, 56 (03) : 221 - 227
  • [7] injury: A systematic review and meta-analysis of randomized controlled trials
    Daou, Marietou
    Dionne, Joanna C.
    Teng, Jennifer F. T.
    Taran, Shaurya
    Zytaruk, Nicole
    Cook, Deborah
    Wilcox, M. Elizabeth
    JOURNAL OF CRITICAL CARE, 2022, 71
  • [8] Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials
    Rosenberg, D.
    Avni, T.
    Tsvetov, G.
    Gafter-Gvili, A.
    Diker-Cohen, T.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (03) : 413 - 424
  • [9] Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials
    Rosenberg, D.
    Avni, T.
    Tsvetov, G.
    Gafter-Gvili, A.
    Diker-Cohen, T.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (10) : 2131 - 2131
  • [10] Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials
    D. Rosenberg
    T. Avni
    G. Tsvetov
    A. Gafter-Gvili
    T. Diker-Cohen
    Osteoporosis International, 2021, 32 : 413 - 424
12345